3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Sezary Syndrome
2
Neoplasms, Plasma Cell
2
Multiple Myeloma
2
Lymphoma, T-Cell, Cutaneous
2
Vascular Diseases
1
Paraproteinemias
1
Neoplasms by Histologic Type
1
Neoplasms
1
Mycosis Fungoides
1
Mesothelioma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hemostatic Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Pemetrexed
5
Nivolumab
4
Cisplatin
4
Carboplatin
4
Ipilimumab
3
durvalumab
1
atezolizumab
1
Vorinostat
1
Talc
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Platinum
1
Injections
1
Cerebral Decortication
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Mesothelioma
×
Vorinostat
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts